IFN b 1a Human

IFN-Beta 1a is produced by mammalian cells, typically Chinese Hamster Ovary (CHO) cells, which have been genetically modified to express the human interferon beta gene . This recombinant protein is glycosylated and has a molecular weight of approximately 22.5 kDa . The amino acid sequence of IFN-Beta 1a is identical to that of natural human interferon beta .

IFN-Beta 1a exerts its effects by binding to the interferon alpha/beta receptor (IFNAR), which is a heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits . Upon binding, it activates the JAK-STAT signaling pathway, leading to the transcription of interferon-stimulated genes (ISGs) that play a crucial role in antiviral defense, immune regulation, and cell proliferation .

The primary clinical application of IFN-Beta 1a is in the treatment of multiple sclerosis (MS). It has been shown to reduce the frequency and severity of MS relapses by modulating the immune response and reducing inflammation . IFN-Beta 1a is also being investigated for its potential use in other autoimmune diseases and certain types of cancer .

Research on IFN-Beta 1a continues to evolve, with ongoing studies exploring its broader applications and optimizing its production. Advances in biotechnology have led to the development of more efficient and cost-effective methods for producing recombinant IFN-Beta 1a with lower endotoxin levels .

Recombinant IFN-Beta 1a is typically stored at -20 to -70 °C to maintain its stability and bioactivity . It is important to avoid repeated freeze-thaw cycles to prevent degradation of the protein .